DrugPatentWatch Database Preview

Daiichi Sankyo Company Profile

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for DAIICHI SANKYO, and when can generic versions of DAIICHI SANKYO drugs launch?

DAIICHI SANKYO has twelve approved drugs.

There are fifteen US patents protecting DAIICHI SANKYO drugs.

There are two hundred and sixty-six patent family members on DAIICHI SANKYO drugs in forty-three countries and forty-seven supplementary protection certificates in fifteen countries.

Summary for Daiichi Sankyo

International Patents:	266
US Patents:	15
Tradenames:	9
Ingredients:	9
NDAs:	12
Patent Litigation for Daiichi Sankyo:	See patent lawsuits for Daiichi Sankyo
PTAB Cases with Daiichi Sankyo as patent owner:	See PTAB cases with Daiichi Sankyo as patent owner

Drugs and US Patents for Daiichi Sankyo

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Daiichi Sankyo Inc	MORPHABOND ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	206544-001	Oct 2, 2015		RX	Yes	No	7,955,619		Y
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		RX	Yes	Yes	7,893,075			Y
Daiichi Sankyo	AZOR	amlodipine besylate; olmesartan medoxomil	TABLET;ORAL	022100-004	Sep 26, 2007	AB	RX	Yes	Yes
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-001	Jan 8, 2015		RX	Yes	No	7,365,205			Y
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		RX	Yes	Yes	10,189,833
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-002	Jan 8, 2015		RX	Yes	No

Expired US Patents for Daiichi Sankyo

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Daiichi Sankyo	WELCHOL	colesevelam hydrochloride	FOR SUSPENSION;ORAL	022362-002	Oct 2, 2009	7,101,960*PED
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	5,580,880
Daiichi Sankyo	WELCHOL	colesevelam hydrochloride	FOR SUSPENSION;ORAL	022362-001	Oct 2, 2009	6,066,678*PED
Daiichi Sankyo	WELCHOL	colesevelam hydrochloride	FOR SUSPENSION;ORAL	022362-002	Oct 2, 2009	5,607,669*PED
Daiichi Sankyo	WELCHOL	colesevelam hydrochloride	CAPSULE;ORAL	021141-001	May 26, 2000	5,607,669*PED
Daiichi Sankyo	TRIBENZOR	amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	200175-001	Jul 23, 2010	5,616,599*PED

Paragraph IV (Patent) Challenges for DAIICHI SANKYO drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Powder for Oral Suspension	1.875 g/Packet and 3.75 g/Packet		2010-04-09
	Tablets	10 mg/20 mg and 5 mg/40 mg		2008-03-31
	Tablets	20 mg/12.5 mg		2007-05-11
	Capsules	30 mg		2009-02-27
	Tablets	15 mg, 30 mg and 60 mg		2019-01-28
	Tablets	625 mg		2009-07-01
	Tablets	5 mg/20 mg and 10 mg/40 mg		2008-02-11
	Tablets	5 mg, 20 mg and 40 mg		2006-04-25
	Tablets	40 mg/12.5 mg and 40 mg/25 mL		2007-02-15
	Tablets	15 mg, 30 mg, 60 mg and 100 mg		2019-01-28

International Patents for Daiichi Sankyo Drugs

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	02085379
Poland	2086972
Poland	2140867
Portugal	1405852
China	1503676
World Intellectual Property Organization (WIPO)	02085377

Supplementary Protection Certificates for Daiichi Sankyo Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1405852	15C0068	France		PRODUCT NAME: EDOXABAN,UN SEL,SOLVATE OU N-OXYDE DE CELUI-CI,EN PARTICULIER L'EDOXABAN TOSYLATE; REGISTRATION NO/DATE: EU/1/15/993 20150619
0480717	98C0025	Belgium		PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
0502314	SPC/GB11/010	United Kingdom		PRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK
1405852	1590052-5	Sweden		PRODUCT NAME: EDOXABAN, A SALT THEREOF, A SOLVATE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE.; REG. NO/DATE: EU/1/15/993/001-028 20150623
1507558	2012/018	Ireland		PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
1915993	300625	Netherlands		PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Daiichi
• Daiichi Sankyo
• Daiichi Sankyo Inc